Jered Weinstock, MD
Pediatric Pulmonology · Anchorage, AKNPI 1952750572
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,792 of the $70,729 with a category attached, or 64.7%. Regeneron Healthcare Solutions, Inc. accounts for 86.7% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2024 at $41,068 and has fallen 61.8% since, to $15,692 in 2025.
Across 213 payments — averaging $332.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$61K
- Insmed, Inc.$1K
- AstraZeneca$1K
- Sekisui Diagnostics LLC$1K
- Baxter Healthcare$1K
- ZOLL Medical Corporation$992
- plus $3K from 25 others
Across 1 payment — averaging $39,010 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$39K
What the payments were for
- Consulting fees$2,9174%
- Speaking & faculty fees$45,79265%
- Travel & lodging$12,63118%
- Food & beverage$7,84511%
- Education$3040%
- Gifts$1,2402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 106 | $61,298 |
| Insmed, Inc. | 16 | $1,405 |
| AstraZeneca(2 entities) | 17 | $1,278 |
| Sekisui Diagnostics LLC | 4 | $1,240 |
| Baxter Healthcare | 17 | $1,206 |
| ZOLL Medical Corporation | 2 | $992 |
| Vertex | 3 | $508 |
| Sanofi | 7 | $365 |
| Teva Pharmaceuticals USA, Inc. | 1 | $285 |
| Cipla USA Inc. | 1 | $215 |
| Electromed, Inc. | 4 | $211 |
| ERBE USA Inc | 1 | $190 |
| Genentech USA, Inc. | 3 | $171 |
| Biogen | 6 | $166 |
| Fisher & Paykel Healthcare Inc | 1 | $158 |
| Mylan Specialty L.p. | 2 | $130 |
| Regeneron | 1 | $125 |
| GSK | 3 | $121 |
| Catalyst Pharmaceuticals, Inc. | 1 | $108 |
| Viatris Specialty LLC | 2 | $96 |
| Springworks Therapeutics, Inc. | 1 | $90 |
| Amgen | 1 | $81 |
| Philips North America LLC | 3 | $64 |
| BD | 1 | $49 |
| Sentynl Therapeutics, Inc. | 1 | $40 |
| Chiesi USA, Inc. | 2 | $36 |
| AbbVie | 2 | $28 |
| Circassia Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Neurelis, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$59,397
- Brinsupri$1,136
- FISHER & PAYKEL HEALTHCARE$792
- Hillrom - Vest System Model 105 Home Care$468
- Hillrom - Life 2000 Ventilation System$215
- ErbeCryo2/VIO3/APC3$190
- Hillrom - Synclara Cough System$118
- TEZSPIRE$109
- FASENRA$109
- AGAMREE$108
How this compares
Too few pediatric pulmonology providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 45 | $1,204,071 |
| ZenpepLipase/Protease/Amylase | 14 | $126,182 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $6,726 |
| Spiriva HandihalerTiotropium Bromide | 11 | $6,396 |
| Azithromycin | 24 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $508 | $1,204,07145 claims |
| GSKTrelegy Ellipta | $121 | $6,72613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric pulmonology providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other pediatric pulmonology in Anchorage
- Dion RobertsAnchorage$234
- Allan AdlerAnchorage$52
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.